



Hvorfor er oppfølging av diabetes i svangerskapet viktig?

Etablert diabetes medfører økt risiko for misdannelser og komplikasjoner i svangerskapet.



Svangerskap ved etablert diabetes. E.Qvistad, OUS


Risk for misdannelser i svangerskapet ved type 1 diabetes



Svangerskap ved etablert diabetes. E.Qvistad, OUS

Nyfødt dødelighet

Så hvorfor virker ikke bedret glykemisk kontroll like bra som vi hadde forventet?



Norwegian Childhood Diabetes Registry
Medical Birth Registry of Norway
Eidem et al. 2011

1975-1998: RR 2.2 (95%CI: 1.4-3.4)
1999-2004: RR 3.1 (95%CI 1.5-6.5)

Svangerskap ved etablert diabetes. E.Qvistad, OUS

Er vektøkning/fettdepoter sentralt?

- Også ved T1DM ses økt pregravid BMI, og forekomst av makrosomi er fortsatt høy tross streng bls regulering. Føtal veksthemming er sjelden utenom ved nefropati eller preeklampsi.

BMI-appropriate gestational weight gain:
12.5–18.0 kg for underweight,
11.5–16.0 kg for normal weight,
7.0–11.5 kg for overweight,
and 5.0–9.0 kg for obese women
(IOM 2009)



Svangerskap ved etablert diabetes. E.Qvistad, OUS

Type 2 diabetes – er sykdommen "snillere"?


Characteristics	n	Type 2 DM	Type 1 DM
Age (yr)	23	33.9	28.8
BMI (kg/m ²)	12	30.2	24.2
DM duration (yr)	15	5.9	11.9
Chronic hypertension (%)	6	11.2	5.5
Retinopathy (%)	13	6.2	25.3
Micro/macrolbuminuria (%)	10	2.9	6.8
Prepregnancy care (%)	11	18.8	34.8
Gestational age at booking (wk)	12	16.2	15.2
HbA _{1c} (%)			
At booking	9	7.20	8.06
Second trimester	4	5.70	6.23
Third trimester	7	5.69	6.00

n, Number of papers contributing to each characteristic.

Svangerskap ved etablert diabetes. E.Qvistad, OUS

Balsells Metaanalysis, JCEM 2009

Gjennomsnittlig insulin dose i svangerskapet (n=107, mean ± SD)



Taylor, R. et al. BMJ 2007;334:742-745

Svangerskap ved etablert diabetes. E.Qvistad, OUS

BMJ

Insulinbehandling i svangerskap

- **Behandlingsmål:** normoglykemi, også etter mat bls 4.0-8.0 mmol/l

- 1. trimester: kvalme, HCG-effekter, ofte behov for dosereduksjon.
- Viktig med hyppige målinger, ofte 8-10 ganger daglig, vurder fortløpende sykmeldingsbehov for å oppnå bedret glykemisk kontroll.
- Stigende insulinbehov (resistens) fra uke 18-20, stabilisering ca. uke 30.
- Nærmest umiddelbart fall i insulinresistens ved partus, må måle hyppig!
- Novorapid og Humalog gir mindre hypoglykemier i svangerskapet, for Apidra/Levemir. Lantus anses trygt. Vi bytter ikke tilbake til Insulatard/Humulin i svangerskapet.
- Pumpebruk går fint.




Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Etablerte mikrovaskulære komplikasjoner

- ofte mer risikable svangerskap


Svangerskap og nefropati

- 5-10% av gravide med diabetes
- Risk for preeklampsi ved MA : 42%, ved proteinuri 64%.
- Skal ha intensiv BT behandling: men det er ikke vist langtidsskade på nyrefunksjon eller påvirket overlevelse av svangerskap (follow up 16 years)



Progresjon av retinopati hos gravide

- Uvanlig <5%, behov for laser terapi 2%
- Oftest forbigående, varer inn i post partum året
- Hyppigere ved diabetes >10 år og moderat/ alvorlig RT



Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Fraråde/vente med svangerskap?

- Nesten ingen !
- Ved alvorlig og ubehandlet øyesykdom (meget få)
- Alvorlig nyresykdom med klart påvirket nyrefunksjon (meget få)
- For alle med diabetes: viktig å planlegge graviditet (HbA1c < 7.0 %)



Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Helsedirektoratet

Alt innhold

Søk i alt innhold

OM OSS

Helsedirektoratet.no > Nasjonale faglige retningslinjer > Diabetes > Svangerskap ved kjent diabetes

Nasjonale faglige retningslinjer for diabetes

Svangerskap ved kjent diabetes

Søk i kapittelet

Planlegging av svangerskapet ved kjent diabetes type 1 og 2 (før svangerskapet)

Sterk anbefaling

Behandlingsmål og henvisningsrutiner ved kjent diabetes type 1 og 2 i svangerskapet

Sterk anbefaling

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

reserveslides

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Takk for oppmerksomheten!


Referanser

- Taylor, R. et al. Type 1 diabetes and pregnancy. BMJ 2007
- Mathiesen, E. et al. Therapeutic management of type 1 diabetes during pregnancy, Exp opin pharmacother 2011.
- Textbook of Diabetes and Pregnancy, Taylor&Francis 2003.
- Jovanović L.: Medical management of pregnancy complicated by diabetes, ADA publications, 4th ed, 2009
- Den norske legeforening: Veileder i fødselshjelp, revidert 2014
- Diabetes håndboken, 2014
- Uptodate
- Nye retningslinjer for diagnostikk og behandling av diabetes HDir 2016



Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Noe å lære ?



AMERICAN DIABETES ASSOCIATION
RACE • RISE • REIMAGINE

MEDICAL MANAGEMENT OF
PREGNANCY
Complicated
by **DIABETES**

- Diagnosis and Classification/Pathogenesis
- Diabetes Standards and Education
- Tools of Therapy
- Special Situations
- Psychosocial Factors Affecting Adherence, Quality of Life, and Well-Being
- Complications
- Emerging Therapies

SVANGERSKAP VED ETABLERET DIABETES.
E. Øvigstad, OUS

FOURTH EDITION

[illegible]

Sammendrag

- Det går mye bedre med type 1 diabetes enn tidligere, men det er fremdeles overhyppighet av perinatal dødelighet, svangerskapsforgiftning og misdannelser
- Mer ressurser til kostveiledning og vektbegrensning?
- Vi må ha flere planlagte svangerskap med $HbA_{1c} < 7.0\%$ før svangerskapet
- Det trengs mer forskning rundt årsakene til diabetes og komplikasjoner i svangerskapet.



Type 2 diabetes svangerskap

- ▶ Perinatal mortalitet 4 x så høy som ved type 1 diabetes
- ▶ Alvorlige misdannelser dobbelt så høy som ved type 1 diabetes.
- ▶ HbA1c assosiert med alvorlig forløp for fosteret
- ▶ To tilfeller av diabetisk ketoacidose ved type 2 !
- ▶ Forløpet ved type 2 diabetes er forverret sammenlignet med perioden 1982-90 !

Clausen et al. Diabetes Care 28;323-328,2005

Svangerskap ved eksisterende diabetes.
E.Ovlgstad, OUS

Svangerskapskomplikasjoner

Diabetes sammenliknet med ikke diabetes (OR)

	Immigrants	Ethnic Norwegians
Preeclampsia	3.6	4.7
Low birth weight	2.6	2.1
Macrosomia	5.5	3.8
Preterm birth	3.0	3.8
Shoulder dystocia	2.5	3.4
Cesarean section	3.0	4.6



Vangen S et al Diabetes care, 2006

Svangerskap ved etablert diabetes.
E.Ovgilstad, OUS

Hindre for prekonsepsjonell veiledning

- Ble gravid fortere enn ventet
- Bekymret for mulig infertilitet
- Negativ erfaring med helsepersonell
- Ønske om et "normalt" svangerskap
- Vansker med å komme til kontroll

Svangerskap ved diabetes
Murphy HR et al: Diabetic Medicine 2010;27:92-100

Glargine, detemir, aspart og lispro i svangerskap:

- Non-inferiority for maternelle og føtale outcomes, gir i noen studier lavere fbbs.
- Langsiktige negative utfall for barna er foreløpig ikke publisert.
- Små studier
- Lite data for glulisine (Apidra).



Lv et al Arch OG: Metaanalyse 2015.

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Insulin behandlet diabetes: post partum

- Svært insulin følsomme (særlig ved oppstart av amming)
- Høy risk for hypoglykemi
- Insulin dose ved hjemreise 60-70% av pregravid dose
- Tilbake til normale doser innen 1-3 mnd
- Post partum kontroll:
BT, albuminuri, øyebunn, prevensjon,

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Kvalme

– gir store problemer

- - vi har begrensede ressurser for KEF veiledning
- Riget har satser mye sterkere på dette (E.Mathiesen)

Table 12 Tips for Controlling Nausea

- Eat dry crackers or toast before rising
- Eat small meals every 2.5–3 h
- Avoid caffeine
- Avoid fatty and spicy foods
- Drink fluids between meals, not with meals
- Take prenatal vitamins after dinner or at bedtime
- Always carry food

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Kostforslag ved kvalme

Table 13 1,800-Calorie Diet to Control Nausea

	Exchanges	Food Source
Before rising	1 Starch	6 crackers or 1 slice bread
Breakfast	1 Meat 2 Starch 1 Fat	1 oz low-fat cheese 2 slices bread or 1 1/2 cups cereal 1 tsp margarine
A.M. snack	1 Starch 1 Milk	3/4 cup cereal 8 oz low-fat milk or plain yogurt
Lunch	2 Meat 1 Vegetable 2 Starch 1 Fat 1 Fruit	1/2 cup tuna or 2 oz turkey or low-fat cheese 1 cup salad or a medium tomato 2 slices bread, 1 cup pasta, or 2/3 cup rice 1 tsp mayonnaise or salad dressing 1/4 cantaloupe, 1 1/4 cup strawberries, or small nectarine
P.M. snack	1/2 Milk 1 Meat 1 Starch	4 oz low-fat milk 1/2 sandwich with 1 oz low-fat meat or cheese or 2 breadsticks with 1 oz low-fat cheese
Dinner	3 Meat 2 Vegetable 2 Starch 1 Fat 1 Fruit	3 oz chicken or lean red meat, baked or broiled 1 cup cooked vegetables (not potatoes, lima beans, peas, or other starch) 2 slices bread, 1 cup pasta, or 2/3 cup rice 1 tsp margarine 1 small peach
Bedtime snack	1/2 Milk 2 Starch 1 Meat	4 oz low-fat milk 2 slices bread 1 Tbsp peanut butter

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Insulinpumpe under fødsel:

- Blodsuktermåling: Som ved aktiv fødsel.
- La basaldosen gå under latensfasen (program a).
- **Halv basaldose** ved aktiv fødsel (program b). Evt koble fra pumpen ved full åpning. Følg tabellen for "behandling av blodsukker" som står under "aktiv fødsel". Dersom kvinnen skal ha insulin -kan insulin dosen gis som bolusdose på pumpen av kvinnen selv. Hvis hun ikke er i stand til å administrere pumpen selv, gis insulin s.c. som vanlig.
- Pumpen må absolutt ikke være fjernet mer enn 2 timer!
- Skulle det oppstå komplikasjoner med pumpen under fødsel (feks. at pasienten ikke får insulin fra pumpen) må blodsukkeret måles og behandling iverksettes utifra tabell ovenfor.
OBS risk for raskt stigende blodsukker med fare for ketoacidose fordi de ikke bruker langsamtvirkende insulin.

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Table 5 Prepregnancy Assessment for Diabetic Women

- History and physical examination
- Gynecologic evaluation
- Laboratory evaluation
 - A1C level
 - Urinalysis and culture
 - 24-h urine for creatinine clearance and total protein
 - Thyroid panel: free T4 1.0–1.6 and TSH <2.5 µU/l
- Special studies
 - Electrocardiogram or treadmill
 - Neuropathy testing if indicated

Table 6 Potential Contraindications to Pregnancy

- Ischemic heart disease
- Active proliferative retinopathy, untreated
- Renal insufficiency: creatinine clearance <50 ml/min or serum creatinine >2 mg/dl or heavy proteinuria (>2 g/24 h) or hypertension (blood pressure >130/80 mmHg despite treatment)
- Severe gastroenteropathy: nausea/vomiting, diarrhea

Svangerskap ved etablert diabetes.
E. Qvigstad, OUS

Planlegge - også for å optimalisere vekt

Table 7 Prepregnancy Diet Calculation

- Determination of daily calorie requirement:
 - 30–34 kcal/kg (2.2 lb) pre-gravid body weight for normal-weight woman (BMI <25)
 - 23–25 kcal/kg (2.2 lb) pre-gravid body weight for obese woman (BMI ≥30)
 - To lose 1 lb/wk, subtract 500 kcal from daily requirement or increase exercise
- Distribution of calories:
 - Variable carbohydrate (consistent amount of daily carbohydrate intake may be beneficial)
 - Saturated fat intake <7% of total calories
 - Intake of trans fat minimized
 - Dietary cholesterol limited to <200 mg/day

Svangerskap ved etablert diabetes.
E.Qvistad, OUS

Svangerskap ved etablert diabetes.
E.Qvistad, OUS


Effekter av graviditet

- Endret spisemønster
- Økt insulin behov fra uke 18-28
- Økt betydning av god glykemisk kontroll (ideelt HbA1c <6.1%)
- Økt risiko for alvorlige hypoglykemier
- Risiko for forverring av etablert retinopati
- Risiko for forverring av etablert nefropati
- Lavere nyreterskel for glukosuri



Svangerskap ved etablert diabetes. Taylor, R. et al. BMJ 2007
E.Qvistad, OUS

Bedret monitoring? Closed loop:



- Stewart, Murphy et al.
- Data ventes 2017

Svangerskap ved etablert diabetes.
E.Qvistad, OUS

Eller et al. BMC Medicine 2015, 13:20
http://www.biomedcentral.com/1745-1001/13/20

Page 5 of 9





Figure 2 Distribution of plasma glucose levels after midnight in young people and adults during (top panel) closed-loop and (bottom panel) conventional insulin-pump therapy. The top panel shows the proportion of values (0.00 to 0.30) on the y-axis and plasma glucose (mmol/l) (2 to 16) on the x-axis. The bottom panel shows the proportion of values (0.00 to 0.30) on the y-axis and plasma glucose (mmol/l) (2 to 16) on the x-axis. Both panels compare closed-loop young (solid line) and closed-loop adults (dashed line) with conventional young (solid line) and conventional adults (dashed line). The top panel shows that closed-loop therapy results in a higher proportion of values in the target range (3.9-6.1 mmol/l) compared to conventional therapy. The bottom panel shows that closed-loop therapy results in a higher proportion of values in the range 3.9-6.1 mmol/l compared to conventional therapy.

Begrense vektøkning: viktig for perinatal morbiditet i T2DM svangerskap?

17 women (29%) gained ≤5 kg, and 41 gained >5 kg. Median GWG was 3.7 kg (-4.7 - 5 kg) and 12.1 kg (5.5-25.5 kg), resp. Prepregnancy BMI was 33.5 kg/m² (30-53) vs. 36.8 kg/m² (30-48), P = 0.037, and median HbA1c 6.7% at first visit in both groups and 5.7 and 6.0%, P = 0.620, in late pregnancy, resp. GWG ≤5 kg was associated with lower birth weight z score (P = 0.008), lower rates of LGA infants (12 vs. 39%, P = 0.041), delivery closer to term (268 vs. 262 days, P = 0.039), and less perinatal morbidity (35 vs. 71%, P = 0.024) compared with pregnancies with GWG >5 kg.

Asbjørnsdottir 2008, Parellada 2014

Svangerskap ved etablert diabetes.
E.Qvistad, OUS



Gestational weight gain (GWG)	Excessive (n = 62)	Appropriate (n = 37)	Insufficient (n = 16)	P value
EQ: oversette	17.7 (10–30)	13.1 (6–16)	8.5 (–2 to 11)	<0.001
Prepregnancy–8 weeks, g/week	257 (–303 to 2,016)	216 (–335 to 515)	87 (–385 to 463)	0.003
8–21 weeks, g/week	405 (42–818)	293 (–177 to 717)	171 (–692 to 338)	<0.001
21–36 weeks, g/week	640 (271–1,173)	444 (27–771)	350 (–100 to 533)	<0.001

Offspring birth weight decreased across the groups 3,681 [2,374–4,500] vs. 3,395 [2,910–4,322] vs. 3,295 [2,766–4,340] g [$P = 0.02$ resp]. In regression analysis, GWG (kg) was associated with offspring birth weight (g) ($\beta = 19$; $P = 0.02$) when adjusted for prepregnancy BMI, HbA_{1c} at 36 weeks, smoking, parity, and ethnicity.

Severe neonatal morbidity was comparable across the GWG groups.

Severely obese and placental diabetes.
Secher DC 2014, OUS


Diabetes og lungemodning

Celeston Chronodose/12mg Betapred
2 doser med 24t intervall.
Øke basal- og måltidsinsulin:

Dag 1 (1. dose Celeston)	Uendret insulinose
Dag 2	Øk med 30% fra utgangsdose
Dag 3	Øk med 40% fra utgangsdose
Dag 4	Øk med 20% fra utgangsdose
Dag 5	Øk med 10% fra utgangsdose
Dag 6	Tilbake til utgangsdose

Bls > 8mmol/l: 4-6 IE ekstra hurtigvirkende

E Qvistad, OUS



Diabetes og forløsning

- Vurder induksjon ved uke 38 (T1DM), bør forløses ved termin
- Latensfase: vanlig insulinregime dersom i form og godt næringsinntak.
- Aktiv fødsel: bls hver time, mål : Glucose goal: 4-6 mmol/l.

- Start glucose infusjon: 50mg/ml/kg kroppsvekt**

Bls <3,5mmol/l	60kg 180ml/t – 80kg 250 ml/t – 100kg 300ml/t
Bls 3,5-6,0 mmol/l	60kg 90ml/t – 80kg 125 ml/t – 100kg 150ml/t
Bls 6,1-8,0 mmol/l	2IE HV insulin sc, dersom høy etter 2t, gjenta etter protokoll.
Bls 8,1-10,0 mmol/l	4IE HV insulin sc, dersom høy etter 2t, gjenta etter protokoll.
Bls >10,0mmol/l	6IE HV insulin sc, dersom høy etter 2t, gjenta etter protokoll.

Bevisstløs? 200mg/ml 40 ml iv umiddelbart, gjenta etter 10min dersom fortsatt bevisstløs.
Stopp infusjon etter fødsel dersom bls <5,0-12,0 mmol/l.

Manglende normalisering av fosterets glukose- og oksygen-konsentrasjoner?

- Fetal and placental weights were increased** in GDM compared to normal (N) pregnancies, despite similar gestational age. Placental histology was consistent with **altered villous morphology**.
- GDM fetuses were significantly **more hypoxic** (O₂ saturation: N 63.2 ± 13.9; GDM 53.8 ± 14.6%, $P < 0.01$; O₂ content: N 5.5 ± 1.4; GDM 4.8 ± 1.2 mmol/l, $P < 0.05$).
- Glucose** (N 3.4 ± 0.5, GDM 3.9 ± 1.2 mmol/l, $P < 0.05$) and **lactate** (N 1.32 ± 0.49; GDM 1.64 ± 0.75 mmol/l, $P < 0.05$) **concentrations were significantly increased** in the umbilical vein in GDM compared to N fetuses.
- Thus, fetuses from gestational diabetic mothers have increased umbilical glucose concentrations **despite normal maternal glucose levels** and a reduction in oxygen saturation and O₂ content together with increased lactate concentration, reflecting altered fetal metabolism.

Suggesting that 'good maternal metabolic control' achieved by currently used methods of monitoring glucose control is not sufficient to ensure a normal oxygenation status and metabolic milieu for the fetus in GDM pregnancies.

Svangerskap ved etablert diabetes.
E.Qvistad, OUS
Tarioch BJOG 2009

Diabetes og blodtrykssykdom i svangerskapet

- Konsensus:**
behandle BT >160 og/eller >105mmHg)

Mild hypertensjon: lite evidens/ingen konsensus.

- Behandling er vist nyttig for **mild hypertensjon ved T1 og T2 diabetes**,
vi sikter derfor mot behandlingsmål <130 and/or <80mmHg

Svangerskap ved etablert diabetes.
Sibai Obstet Gynecol 2002/J Mat Fetal Med 2010

Strengere/mer detaljert insulinregime?

Table 9 Insulin Dosage Regimen for Diabetic Pregnancy

Frequency NPH plus rapid acting insulin schedule

Patient weight is kg = _____ Date and time: _____

Big 1 = total daily units of insulin _____
Big 2 = total daily units of insulin _____
Big 3 = total daily units of insulin _____
Big 4 = total daily units of insulin _____
Big 5 = total daily units of insulin _____
Big 6 = total daily units of insulin _____
Big 7 = total daily units of insulin _____
Big 8 = total daily units of insulin _____
Big 9 = total daily units of insulin _____
Big 10 = total daily units of insulin _____
Big 11 = total daily units of insulin _____
Big 12 = total daily units of insulin _____
Big 13 = total daily units of insulin _____
Big 14 = total daily units of insulin _____
Big 15 = total daily units of insulin _____
Big 16 = total daily units of insulin _____
Big 17 = total daily units of insulin _____
Big 18 = total daily units of insulin _____
Big 19 = total daily units of insulin _____
Big 20 = total daily units of insulin _____
Big 21 = total daily units of insulin _____
Big 22 = total daily units of insulin _____
Big 23 = total daily units of insulin _____
Big 24 = total daily units of insulin _____
Big 25 = total daily units of insulin _____
Big 26 = total daily units of insulin _____
Big 27 = total daily units of insulin _____
Big 28 = total daily units of insulin _____
Big 29 = total daily units of insulin _____
Big 30 = total daily units of insulin _____
Big 31 = total daily units of insulin _____
Big 32 = total daily units of insulin _____
Big 33 = total daily units of insulin _____
Big 34 = total daily units of insulin _____
Big 35 = total daily units of insulin _____
Big 36 = total daily units of insulin _____
Big 37 = total daily units of insulin _____
Big 38 = total daily units of insulin _____
Big 39 = total daily units of insulin _____
Big 40 = total daily units of insulin _____
Big 41 = total daily units of insulin _____
Big 42 = total daily units of insulin _____
Big 43 = total daily units of insulin _____
Big 44 = total daily units of insulin _____
Big 45 = total daily units of insulin _____
Big 46 = total daily units of insulin _____
Big 47 = total daily units of insulin _____
Big 48 = total daily units of insulin _____
Big 49 = total daily units of insulin _____
Big 50 = total daily units of insulin _____
Big 51 = total daily units of insulin _____
Big 52 = total daily units of insulin _____
Big 53 = total daily units of insulin _____
Big 54 = total daily units of insulin _____
Big 55 = total daily units of insulin _____
Big 56 = total daily units of insulin _____
Big 57 = total daily units of insulin _____
Big 58 = total daily units of insulin _____
Big 59 = total daily units of insulin _____
Big 60 = total daily units of insulin _____
Big 61 = total daily units of insulin _____
Big 62 = total daily units of insulin _____
Big 63 = total daily units of insulin _____
Big 64 = total daily units of insulin _____
Big 65 = total daily units of insulin _____
Big 66 = total daily units of insulin _____
Big 67 = total daily units of insulin _____
Big 68 = total daily units of insulin _____
Big 69 = total daily units of insulin _____
Big 70 = total daily units of insulin _____
Big 71 = total daily units of insulin _____
Big 72 = total daily units of insulin _____
Big 73 = total daily units of insulin _____
Big 74 = total daily units of insulin _____
Big 75 = total daily units of insulin _____
Big 76 = total daily units of insulin _____
Big 77 = total daily units of insulin _____
Big 78 = total daily units of insulin _____
Big 79 = total daily units of insulin _____
Big 80 = total daily units of insulin _____
Big 81 = total daily units of insulin _____
Big 82 = total daily units of insulin _____
Big 83 = total daily units of insulin _____
Big 84 = total daily units of insulin _____
Big 85 = total daily units of insulin _____
Big 86 = total daily units of insulin _____
Big 87 = total daily units of insulin _____
Big 88 = total daily units of insulin _____
Big 89 = total daily units of insulin _____
Big 90 = total daily units of insulin _____
Big 91 = total daily units of insulin _____
Big 92 = total daily units of insulin _____
Big 93 = total daily units of insulin _____
Big 94 = total daily units of insulin _____
Big 95 = total daily units of insulin _____
Big 96 = total daily units of insulin _____
Big 97 = total daily units of insulin _____
Big 98 = total daily units of insulin _____
Big 99 = total daily units of insulin _____
Big 100 = total daily units of insulin _____

Svangerskap ved etablert diabetes.
E.Qvistad, OUS

Svangerskapsplanlegging

– er vi gode nok?

■ With proper counseling and management by the primary care physician, the outcome of most pregnancies complicated by diabetes can approach that for the general population.

■ General guidelines for pre-pregnancy counseling and management of women with preexisting diabetes are:

• Ensure that pregnancy is planned, counsel the woman about contraception methods.

• Clearly identify for the woman and her partner the risks of congenital anomalies and spontaneous abortions and their relation to glucose control.

• Provide realistic information about chronic complications of type 1 diabetes, their potential impact on pregnancy and childbearing, and the effect of pregnancy on chronic complications.

• Assess the woman's fitness for pregnancy, paying special attention to retinopathy, nephropathy, hypertension, neuropathy, and ischemic heart disease.

• Identify any gynecologic abnormalities before conception, and treat infertility as early as possible in view of the risk to pregnancy associated with increasing duration of diabetes.

Source: American Diabetes Association. Standards of Medical Care for Patients with Diabetes Mellitus. 2014.

factors permitting, pregnancy should be encouraged.

• Provide genetic counseling, including the risks of advanced maternal age, if applicable.

• Provide realistic information about additional medical costs associated with a pregnancy complicated by diabetes, such as extra office visits, possible hospitalization, special tests, and possible intensive neonatal care.

• Achieve optimum control of blood glucose levels before conception. Ideally, A1C should be normal or near normal before discontinuing contraception.

• Encourage good general principles of health, nutrition, and hygiene, including cessation of smoking and alcohol consumption. Prescribe a prenatal vitamin with folate as part of the preconception treatment plan.

• Identify any problems requiring psychosocial consultation.

• Once the decision is made to attempt pregnancy, provide appropriate optimism that careful glycemic control and meticulous obstetric care results in an excellent outcome in the vast majority of patients.

• Diagnose pregnancy as early as

Table 1—Primary and secondary outcomes during closed-loop and conventional CSII

	Closed-loop delivery	CSII	P
Primary outcome			
Plasma glucose time in target			
Percentage of time in target (63–140 mg/dL)	81 (59–88)	81 (54–80)	0.75
Secondary outcomes			
Plasma glucose outcomes			
Mean plasma glucose (mg/dL)	108 (99–121)	104 (92–108)	0.35
SD of plasma glucose (mg/dL)	25.2 (23.4–37.8)	28.8 (25.2–41.4)	0.69
Hypoglycemia			
Percentage of time hypoglycemic <63 mg/dL	6.9 (1.3–12)	7.5 (3.6–18)	0.48
Percentage of time hypoglycemic ≤50 mg/dL	0.6 (0.0–2.1)	1.5 (0.0–2.7)	0.17
Percentage of time hypoglycemic ≤45 mg/dL	0.0 (0.0–0.2)	0.3 (0.0–1.5)	0.04
Symptomatic hypoglycemia	8	17	
Episodes >45–54 mg/dL	8	12	
Episodes >36–45 mg/dL	5	5	
Episodes <36 mg/dL	0	3	
LIQ*	2.4 (0.9–3.5)	3.3 (1.9–5.1)	0.03
Hyperglycemia			
Percentage of time hyperglycemic >140 mg/dL	14.0 (6.6–28)	6.7 (5.6–22)	0.75
Percentage of time hyperglycemic ≥180 mg/dL	0.2 (0.0–0.0)	0.0 (0.0–6.2)	0.78
High blood glucose index	0.8 (0.3–1.6)	0.4 (0.3–1.4)	0.81
PAEE (kJ/kg)	23.4 (19.7–27.0)	21.2 (19.0–22.1)	0.09
Insulin			
Insulin infusion (units/h)	0.7 (0.5–0.9)	0.8 (0.5–1.1)	0.35
SD insulin infusion rate	0.9 (0.5–1.0)	0.2 (0.2–0.5)	<0.001
Plasma insulin concentration	120 (101–146)	107 (82–149)	0.88

Data are median (interquartile range), unless otherwise indicated. *LIQ assessed the duration and extent of hypoglycemia.

2528 DIABETES CARE, VOLUME 34, DECEMBER 2011 Svangerskapsplanlegging ved etablert diabetes. E. Qvistad, OUS care.diabetesjournals.org

Evaluation of screening and progression of diabetic retinopathy during pregnancy in Irish women with pregestational diabetes

- Observational, n=185
- Attendance at prepregnancy care was associated with receiving adequate screening (odds ratio 6.23; CI 3.39–11.46 (P < 0.001)).
- Among those who received adequate evaluations (n = 185), 48 (25.9%) had retinopathy progression.
- Increasing booking systolic blood pressure (OR 1.03, CI 1.01–1.06, P = 0.02) and greater drop in HbA1c between first and third trimesters of pregnancy (OR 2.05, CI 1.09–3.87, P = 0.03) significantly increased the odds of progression.
- A significant proportion of women continue to demonstrate retinopathy progression during pregnancy.

Svangerskap ved etablert diabetes. E. Qvistad, OUS

Egan AM J Diab Res 2015

ISRCTN83316328 DOI 10.1186/ISRCTN83316328

Closed-loop in pregnancy day and night home feasibility study (CLIP 24/7)

Condition category	Prospective/Retrospective
Pregnancy and Childbirth	Prospectively registered
Date applied	Overall trial status
07/01/2016	Ongoing
Date assigned	Recruitment status
08/01/2016	Recruiting
Last edited	
08/01/2016	

Plain English Summary

Background and study aims

Controlling blood sugar levels during pregnancy is very important for the health of the mother and the baby. However, many women with type 1 diabetes find it hard to avoid high blood sugar levels without experiencing low blood sugar levels (hypoglycaemia). Closed-loop systems consist of a continuous glucose monitor (CGM), a computer algorithm (mathematical instructions which calculate the insulin dose) and an insulin pump. During closed-loop, the CGM measures the glucose levels and relays them to the computer. The computer calculates an appropriate insulin dose according to the algorithm. It communicates with the insulin pump to give out the particular dose of insulin every 12 minutes. The closed-loop system has already been tested in women with type 1 diabetes during early, mid and late pregnancy. How it adapts insulin for the changing needs of pregnancy both in hospital and at home overnight has already been studied. In addition, a

study similar in design to this one has tested the use of overnight closed-loop insulin delivery compared with using an insulin pump and continuous glucose monitor alone. It was designed to test that the technology was safe and worked well.

Table 2 Goals to improve gradually closed-loop performance

Factor	Desirable improvements
Insulin delivery	Faster absorption
Glucose sensing	Increased accuracy and reliability; reduced false-positive hypoglycemia alarms
Insulin modulation	Adaptive algorithms
Dual-hormone systems	Dual-hormone pumps
Communication between glucose sensor and insulin pump	More reliable connectivity; standardized communication protocol
Human factors	Reduced size of device; enhanced ease of use; sensing and delivery from a single body port

Svangerskap ved etablert diabetes. E. Qvistad, OUS

Insulinkarakteristika

Table 23 Insulins by Comparative Action

	Onset (h)	Peak (h)	Effective duration (h)
Rapid acting [manufacturer]			
Insulin lispro (analog) [Lilly]	<0.3–0.5	0.5–2.5	3–6.5
Insulin aspart (analog) [Novo Nordisk]	<0.25	0.5–1	3–5
Insulin glulisine (analog) [Sanofi Aventis]	<0.25	1–1.5	3–5
Short acting			
Regular (soluble) [Lilly, Novo Nordisk]	0.5–1	2–3	3–6
Intermediate acting			
NPH (isophane) [Lilly, Novo Nordisk]	2–4	4–10	10–16
Long acting			
Insulin glargine (analog) [Aventis]	2–4	Relatively flat	20–24
Insulin detemir (analog) [Novo Nordisk]	0.8–2 (dose dependent)	Relatively flat	Dose dependent; 12 h for 0.2 U/kg; 20 h for 0.4 U/kg; up to 24 h. Binds to albumin.
Combinations			
50% NPH, 50% regular [Lilly]	0.5–1	Dual	10–16
70% NPH, 30% regular [Lilly]	0.5–1	Dual	10–16
75% NPL, 25% lispro [Lilly]	<0.25	Dual	10–16
50% NPL, 50% lispro [Lilly]	<0.25	Dual	10–16
70% aspart protamine, 30% aspart [Novo Nordisk]	<0.25	Dual	15–18

Svangerskap ved etablert diabetes. E. Qvistad, OUS

Hypertensjon: Behandling

- Hvile, saltfattig diett
- KI: ACE-I / ATBR2
- **Hyppigst brukt:**
Labetalol tabl. 100 mg x 2, opp til 200 mg x 2-3.
Max plasmakonsentrasjon etter 1-2 t.
- Nifedipin tabl 10 mg x 2, opp til max 40 mg x 2/24t. Effekt etter 45-60 min. Retard preparat: 30 mg x 1 evt. 30 mg x 2
- Metyldopa tabl. 250 mg x 2-3. Opp til 500 mg x 3. Effekt etter 3-8 t, full effekt 12 t.
- Vurder kombinasjon for å redusere BV

Veileder i fødselshjelp 2014

Svangerskap ved etablert diabetes.
E.Qvigstad, OUS

Closed loop day and night feasibility study (CLIP 24/7) Cambridge, UK

Primary outcome measures

Time spent in the target glucose range from 3.5-7.8 mmol/L, as recorded by continuous glucose monitoring (CGM) during the 28 day intervention periods.

Secondary outcome measures

1. Time with glucose levels in the hypoglycaemic range, based on continuous glucose monitoring (glucose levels < 2.8 mmol/L)
2. Time with glucose levels in the hyperglycaemic range, based on continuous glucose monitoring (glucose levels > 7.8 mmol/L)
3. Metabolic control assessed by change in HbA1c. **EQ: oversette** system for 28 days, compared with that during continuous glucose monitoring without the closed-loop system for 28 days. HbA1c will be measured before and after each intervention arm
4. CGM data collected during intervention arms will be compared to baseline CGM readings
5. Trends in CGM data collected within intervention arms will also be evaluated on weekly basis (i.e. week 1 versus week 2 versus week 3 versus week 4)
6. CGM data collected after the intervention arms i.e. during pregnancy and up to 6 weeks post-partum will also be compared to baseline and intervention arm readings using CGM summary statistics and functional data analyses

Overall trial start date

01/06/2015

Overall trial end date

31/12/2016

Svangerskap ved etablert diabetes.
E.Qvigstad, OUS